Environmental elimination estimate and literature review of ecotoxicological aspects of the main widely used antiretrovirals in Brazil

Estimativa de eliminação no meio ambiente e revisão de literatura de aspectos ecotoxicológicos dos principais antirretrovirais mais utilizados no Brasil

Estimación de la eliminación en el medio ambiente y revisión de la literatura sobre aspectos ecotoxicológicos de los principales fármacos antirretrovirales más utilizados en Brasil

Received: 07/14/2022 | Reviewed: 07/24/2022 | Accept: 07/26/2022 | Published: 08/04/2022

Cléssius Ribeiro de Souza ORCID: https://orcid.org/0000-0003-0884-1202 Federal University of Minas Gerais, Brazil E-mail: clessiusdcq@gmail.com Matheus de Freitas Ribeiro ORCID: https://orcid.org/0000-0001-8603-1999 Federal University of Minas Gerais, Brazil E-mail: matheusfribeiro@gmail.com Míriam de Fátima Soares ORCID: https://orcid.org/0000-0001-9973-9603 Federal Center for Technological Education of Minas Gerais, Brazil E-mail: mfsquimica2@gmail.com Simone Furtado dos Santos ORCID: https://orcid.org/0000-0002-2060-5934 Federal University of Minas Gerais, Brazil E-mail: simonefurtadofarmaceutica@gmail.com Cíntia Aparecida de Jesus Pereira ORCID: https://orcid.org/0000-0003-3404-9059 Federal University of Minas Gerais, Brazil E-mail: cintiajp@icb.ufmg.br Marcos Paulo Gomes Mol ORCID: https://orcid.org/0000-0002-2568-3579 Ezequiel Days Fundation, Brazil E-mail: marcos_mol@yahoo.com.br **Micheline Rosa Silveira** ORCID: https://orcid.org/0000-0001-7002-4428 Federal University of Minas Gerais, Brazil E-mail: michelinerosa@gmail.com

Abstract

Objective: To estimate the consumption and quantity of unaltered antiretrivirals (ARV) eliminated into the environment and to carry out a literature research on aquatic ecotoxicological studies of ARV used in Brazil. Methodology: We requested from one of the ARV dispensing units in the city of Belo-Horizonte (BH) the amount of ARV dispensed in the years 2018-2019-2020. Considering the amount dispensed in 2020, the daily dose, and the elimination rate, the amount of drug in unchanged form in the environment was estimated. For entire municipality of BH and Brazil, we used epidemiological data were used regarding individuals using antiretroviral therapy (ART) in 2020, the proportion of people living with HIV using the main ART regimen, following the same estimation methodology used previously. Structured and individual searches were carried out for each ARV used in Brazil, relating it to ecotoxicology, through Google Scholar, National Center for Biotechnology Information and Scifinder, in addition to the use of the fass.se platform. Results: Four articles presented results of acute or chronic toxicity in ecotoxicological models involving ARV. Dolutegravir and efavirenz were found to be highly toxic in ecotoxicological models. In 2020, approximately 2,163kg of ARVs in unchanged form were released into the environment in BH. In Brazil it was 112,276kg. Conclusion: It is urgent to quantify the main ARV in water bodies. With these data together with ecotoxicological data it will be possible to establish risk criteria for possible measures to control or mitigate these contaminants in the environment, especially actions to improve wastewater/water treatment. Keywords: Antiretrovirals; Ecotoxicology; Environment.

Resumo

Objetivo: Estimar o consumo e a quantidade de antirretrovirais (ARV) eliminados inalterados no meio ambiente e realizar uma pesquisa bibliográfica sobre estudos de ecotoxicologia aquática de ARV utilizados no Brasil. Metodologia: Solicitamos em uma das unidades dispensadoras de ARV da cidade de Belo Horizonte (BH) a quantidade de ARV dispensada nos anos de 2018-2019-2020. Considerando a quantidade dispensada em 2020, a dose diária e a taxa de eliminação, foram estimadas as quantidades de fármaço na forma inalterada no ambiente. Para todo o município de BH e Brasil, foram utilizados dados epidemiológicos referentes aos indivíduos em uso de terapia antirretroviral (TARV) em 2020, a proporção de pessoas vivendo com HIV em uso do regime principal de TARV, seguindo a mesma metodologia de estimativa utilizada anteriormente. Foram realizadas buscas estruturadas e individuais para cada ARV utilizado no Brasil, relacionando-o à ecotoxicologia, por meio do Google Scholar, National Center for Biotechnology Information e Scifinder, além do uso da plataforma fass.se. Resultados: Quatro artigos apresentaram resultados de toxicidade aguda ou crônica em modelos ecotoxicológicos envolvendo ARV. Dolutegravir e efavirenz foram considerados altamente tóxicos. Em 2020, aproximadamente 2.163kg de ARV na forma inalterada foram liberados no meio ambiente em BH. No Brasil foram 112.276kg. Conclusão: É urgente quantificar os principais ARV em corpos d'água. Com esses dados, somados aos dados ecotoxicológicos será possível estabelecer critérios de risco para possíveis medidas de controle ou mitigação desses contaminantes no meio ambiente, especialmente ações de melhoria nos tratamentos de esgoto/águas. Palavras-chave: Antirretrovirais; Ecotoxicologia; Meio ambiente.

Resumen

Objetivo: Estimar el consumo y la cantidad de antirretrovirales (ARV) eliminados inalterados en el medio ambiente y realizar una búsqueda bibliográfica sobre estudios de ecotoxicología acuática de los ARV utilizados en Brasil. Metodología: Solicitamos en una de las unidades de dispensación de ARV en la ciudad de Belo-Horizonte (BH) la cantidad de ARV dispensada en los años 2018-2019-2020. Considerando la cantidad dispensada en 2020, la dosis diaria y la tasa de eliminación, se estimó la cantidad de fármaco en forma inalterada en el medio ambiente. Para todo el municipio de BH y Brasil, se utilizaron los datos epidemiológicos de las personas que utilizan la terapia antirretroviral (TARV) en 2020, la proporción de personas que viven con el HIV que utilizan el régimen principal de TARV, siguiendo la misma metodología de estimación utilizada anteriormente. Se realizaron búsquedas estructuradas e individuales para cada ARV utilizado en Brasil, relacionándolo con la ecotoxicología, a través de Google Scholar, Centro Nacional de Información Biotecnológica y Scifinder, además del uso de la plataforma fass.se. Resultados: Cuatro artículos presentaron resultados de toxicidad aguda o crónica en modelos ecotoxicológicos que involucran ARV. Se encontró que dolutegravir y efavirenz son altamente tóxicos. En 2020, aproximadamente 2.163kg de ARV sin cambios se liberaron al medio ambiente en BH. En Brasil fue de 112.276kg. Conclusión: Es urgente cuantificar los principales ARV en cuerpos de agua. Con estos datos, sumados a los datos ecotoxicológicos, será posible establecer criterios de riesgo para posibles medidas de control o mitigación de estos contaminantes en el medio ambiente, especialmente actuaciones para mejorar los tratamientos de aguas residuales/aguas.

Palabras clave: Antirretrovirales; ecotoxicología; Ambiente.

1. Introduction

We have observed exponential growth of new drugs and volume produced worldwide with increasing scientific and technological development (Akkari, et al., 2016; Kornis, et al., 2014). The benefits of developing medicines, health products, detergents, disinfectants, surfactants, pesticides, and other organic compounds are evidenced by the improved quality of life of humans, domestic animals, and animals for agricultural activity. However, the cycle of production and consumption generates new types of waste, namely, persistent organic pollutants (POPs) (Tang et al., 2019).


POPs are organic compounds resistant to environmental degradation through biological, chemical, and photolytic processes generating toxicity (RASHED, 2022). An example is the chemical and pharmaceutical industry's production process residues, inappropriately discarded medicines, and their metabolites associated with consumption (Jain, et al., 2013; Ncube, et al., 2018; Rashed, 2022). Due to their persistence, POPs can bioaccumulate and adversely affect human health and the environment (Rashed, 2022).

Regarding antiviral (ANV) and antiretroviral (ARV) drugs, we highlight drugs used for the treatment of HIV infection. Approximately 37.6 million people worldwide are currently living with the virus. Of these, 27.4 million are on antiretroviral therapy (ART). Brazil has approximately 920,000 people with the virus, of which 665,000 are on ART (BRASIL, 2020; UNAIDS, 2021). The use of ART is essential for people living with HIV (PLHIV). However, the waste generated should

not be disregarded since it can be associated with generating drug-resistant viral strains. Moreover, they can unbalance the ecosystem, triggering new problems (Kumar et al., 2021; Nannou et al., 2020). Several studies have indicated the presence of ARVs in drinking water and raw water, such as those from rivers, lakes, ponds, and groundwater (Jain et al., 2013; Nannou et al., 2020; Prasse, et al., 2010). A recent literature review performed by Nannou et al. (2020) revealed the presence of ANVs and ARVs in the environment in several studies, and most are concentrated in Europe and South Africa, with 22 and 13 studies, respectively. Central America and South America did not present any relevant study selected by the authors (Nannou et al., 2020).

Estimating pollutants' effects on ecosystems occurs mainly through ecotoxicological tests, using organisms found in the atmosphere, lithosphere, and mainly hydrosphere (Costa, et al., 2008; Gazola, 2020). Most plants for the treatment of effluents containing the new pollutants use conventional sewage treatment methodologies adopted by sanitation companies, which remove organic loads through biological processes. However, they are not consistently effective for the removal of recalcitrant substances. Other processes that include the use of technology, such as advanced oxidative processes, which aim to degrade recalcitrant substances, can be used instead of or associated with conventional processes (Brito & Marinho Silva, 2012; Fioreze, et al., 2014; Von Sperling, 1996).

ARVs reach the environment through waste disposal from the pharmaceutical industry production process (industrial effluent), hospital effluent, and elimination of drugs in unchanged form or through metabolites. Furthermore, the improper disposal of medicines is a source of contamination of the environment (Aquino, et al., 2013; Jain et al., 2013; Ncube et al., 2018). Figure 1 represents the cycle of drugs in the environment after dispensing for consumption and its potential consequences.





POPs: Persistent organic pollutants; HHW: Household hazardous waste; WTS: Water Treatment Station; WWT: Wastewater treatment Source: Adapted from Aquino, Brandt, & Chernicharo (2013)

The impact of these pollutants on the environment can be curbed through the effective treatment of waste and effluents and proper final disposal management. In Brazil, Resolution N° 430 of the National Council for the Environment (CONAMA), of May 13, 2011, requires prior treatment of waste to be disposed of by industries and hospitals (CONAMA, 2011b). Regarding domestic sewage, although universal sanitation is provided for in the Constitution and guaranteed by Law 11,445/2001, in practice, we can observe the lack of universal sewage collection and treatment. According to the *Trata Brasil* Institute, only 54.1% of the Brazilian population has access to adequate sewage collection, and 49.1% of the sewage produced has adequate treatment (Instituto Trata Brasil, 2021). Although some methodologies to mitigate the load of waste released into the environment are in place, an assessment of their efficiency and possible effects on aquatic life is required (CONAMA, 2011b; Gazola, 2020).

1.1 Brazilian legislation and standards for ecotoxicology

The term ecotoxicology was proposed during a meeting in Stockholm at the Committee of the International Council of Scientific Unions (ICSU) in June 1969 by French researcher René Truhaut (Truhaut, 1977 apud Magalhães & Filho, 2008). Truhaut (1977) argues that ecotoxicology is a branch of toxicology, which seeks to study the toxic effects of natural or synthetic pollutants on life in general, whether microbiological, plant or animal. It is a tool to assess the impact of pollutants on the environment and predict possible future damage, thus considering the various interactive possibilities (Magalhães & Ferrão-Filho, 2008; Zagatto & Bertoletti, 2006).

Ecotoxicological tests with aquatic organisms are traditionally used to assess the effect of specific substances or a set of them and contaminated waters. Tests performed with specific substances are used to obtain chemical records, while tests with water are used to obtain data regarding the compliance of the water body or industrial effluent. Toxicity data help evaluate and compare the susceptibility of the aquatic organism to different substances (Costa et al., 2008).

Currently, several environmental protection agencies work on developing and standardizing these tests to organize environmental protection strategies. Some of the international organizations engaged in this work are the United States Environmental Protection Agency (US EPA), the American Society for Testing and Materials (ASTM), the Organization for Economic Cooperation and Development (OECD), the Association of Analytical Communities (AOAC), and the International Organization for Standardization (ISO). In Brazil, the organization responsible for developing and standardizing toxicological testing protocols is the Brazilian Association of Technical Norms (ABNT) and CETESB, which also carries out some standardization work (Costa et al., 2008).

For ecotoxicological tests, the test should be conducted on more than one aquatic biota species, preferably belonging to different trophic levels, such as producers, primary consumers, and secondary consumers. Decomposers such as bacteria and rotifers can also be used besides organisms of different trophic levels (Costa et al., 2008). In Brazilian legislation, the resolutions of the National Council for the Environment (CONAMA) RE 357/2005 and RE 430/2011 establish the possibility of using biological indicators, toxicity tests for interactions of compounds not listed in the resolution, and running ecotoxicological tests in effluents using aquatic organisms of at least two different trophic levels. Box 1 shows the list of the leading Brazilian standards for aquatic ecotoxicological tests (ABNT, 2022; CONAMA, 2005, 2011a)

| Effect | aquatic organism | Species | Trophic level | Rule | | |
|---------|---------------------|--|--------------------|---------------------|--|--|
| Chronic | Fish | Danio rerio, Pimephales promelas | Secondary consumer | ABNT NBR 15499:2022 | | |
| Acute | Fish | Danio rerio, Pimephales promelas | Secondary consumer | ABNT NBR 15088:2022 | | |
| Acute | Crustacea | Daphnia similis, Daphnia magna | Primary consumer | ABNT NBR 12713:2022 | | |
| Acute | Crustacea | Amphipod | Primary consumer | ABNT NBR 16638:2021 | | |
| Acute | Crustacea | Artemia sp | Primary consumer | ABNT NBR 16530:2021 | | |
| Chronic | Alga | Marine microalgae | Primary producer | ABNT NBR 16181:2021 | | |
| Acute | Crustacea | Marine copepods | Primary consumer | ABNT NBR 16723:2021 | | |
| Acute | Bacteria | Aliivibrio fischeri | Decomposer | ABNT NBR 15411:2021 | | |
| Chronic | Crustacea | Hyalella spp | Primary consumer | ABNT NBR 15470:2021 | | |
| Chronic | Echinoderm | Lytechinus variegatus, Arbacia lixula e Echinometra lucunter | Primary consumer | ABNT NBR 15350:2020 | | |
| Chronic | Alga | Chlorella vulgaris, Scenedesmus subspicatus, Pseudokirchneriella subcapitata | Primary producer | ABNT NBR 12648:2018 | | |
| Acute | Crustacea | Misideos | Primary consumer | ABNT NBR 15308:2017 | | |
| Chronic | Crustacea | Ceriodaphnia dúbia, Ceriodaphnia silvestrii | Primary consumer | ABNT NBR 13373:2016 | | |
| Acute | Bivalve mollusc | Perna perna | Primary consumer | ABNT NBR 16456:2016 | | |
| Acute | Crustacea | Marine amphipods | Primary consumer | ABNT NBR 15638:2015 | | |

Box 1. Brazilian standardized aquatic ecotoxicology tests.

Source: Authors (2022).

Toxicity tests aim to understand the toxic effects of substances on organisms. These tests can assess acute and chronic toxicity. The acute toxicity test evaluates the effects of substances on organisms in a short period as these effects result from single or multiple contacts within 24-96 hours. The parameters evaluated are usually mortality or immobility and metabolic changes or biochemical reactions. The results of these tests can be expressed as LC_{50} (mean lethal concentration), EC_{50} (mean effective concentration), IC_{50} (mean inhibitory concentration), and LD_{50} (mean lethal dose); in other words, the concentration of the substance causing death, immobility, or 50% growth inhibition of test organisms after a specific exposure time (Costa et al., 2008; Gazola, 2020).

Chronic toxicity tests assess the effects of long-term exposure to the substances studied, covering their entire life cycle or part of it. They are used for evaluating sublethal doses, for example, for evaluating treated effluent, since the exposure of organisms to low concentrations does not eliminate the risk of deleterious effects (Costa et al., 2008). The main objective is to understand the effects on the life cycle of organisms, such as, for example, whether there are biological function (reproduction, egg development, and maturation) disorders. Furthermore, they help study the pollutants' bioaccumulation capacity and their carcinogenic and mutagenic potential (Zenker, et al., 2014). Thus, assessing chronic toxicity is crucial to complement the acute toxicity test and obtain adequate information about the studied agents. Chronic toxicity tests are performed for seven to 21 days. Results are usually expressed as NOEC (no observed effect concentration), the highest concentration of toxic agent that does not cause statistically significant deleterious effect on organisms at exposure time and

test conditions, and LOEC (lowest observed effect concentration), the lowest concentration of the toxic agent, which causes a statistically significant deleterious effect on organisms at the time of exposure and test conditions, but the results can be expressed as EC_{50} (Costa et al., 2008; Gazola, 2020).

This study aimed to estimate the consumption and amount eliminated in the ARV's unchanged form to the environment in Belo Horizonte and Brazil and search in the scientific literature, in an integrative way, to obtain an overview and more up-to-date ecotoxicological studies on the aquatic environment involving the ARVs used in Brazil.

2. Methodology

2.1 Estimated consumption and elimination of antiretrovirals in Brazil

Due to the difficulty of accurately establishing the amount of ARV consumed, one of the ways to estimate the consumption of medicines is through direct dispensing information from ARV distribution centers. We requested the amount of ARV dispensed in 2018, 2019, and 2020 from one of the ARV dispensing units in Belo Horizonte, Brazil, which provides clinical and outpatient care to PLHIV and those affected by other infectious diseases. Based on the volume dispensed last year, the recommended daily dose of each drug and the elimination rate, we estimated the drug volume in the environment for the municipality studied. The annualized results were obtained by multiplying the recommended daily dose, the percentage eliminated in unchanged form, and the estimated number of pharmacotechnical units dispensed per year, dividing them by one million to express the values in kilograms.

The number of specific ARVs consumed was unavailable for general data related to Belo Horizonte and Brazil, which hampered obtaining estimates of the amount released by these drugs into the environment. Epidemiological data referring to the number of individuals using ART in 2020 in Belo Horizonte and Brazil were employed to estimate the amount of antiretroviral dispensed in the environment, applying the same mathematical equation for quantifying ARVs in the ARV dispensation health unit in Belo Horizonte.

2.2 Ecotoxicity studies

The integrative review was used as method of the research, that consists of building a broad analysis of the literature, contributing to discussions about research methods and results, as well as reflections on carrying out new studies (Cronin & George, 2020; Whittemore & Knafl, 2005).

All the most used ARVs in Brazil were selected and included in the National List of Essential Medicines (RENAME 2020) to conduct the bibliographic search (BRASIL, 2019). After defining which ARVs would be evaluated, we searched for each drug individually on Google Scholar, National Center for Biotechnology Information (NCBI), and SciFinder platforms. The following descriptors were used on Google Scholar for the search strategy: (name of antiretroviral) AND ecotoxicology OR ecotoxicological. In the NCBI, we used: ((Name of the antiretroviral) AND (ecotoxicological) OR (ecotoxicity) OR (ecotoxicology)). In SciFinder, with each of the terms being searched individually, we used: (antiretroviral name) AND ecotoxicology, (antiretroviral name) AND ecotoxicity, (antiretroviral name) AND ecotoxicological. We included for evaluation publications on any date up to 2021; scientific papers; full-text in English or Portuguese; papers that presented results for ARV toxicity tests included in the RENAME 2020 list, for some test organisms, indicating the concentration of acute or chronic toxicity; papers with information on the initial concentration and after the effluent treatment, of at least one ARV on the RENAME 2020 list. We excluded incomplete texts or texts in other languages, theses, books, literature review papers, and toxicity estimation studies conducted using software if the paper was carried out only for this purpose. Ecotoxicological information on ARVs registered in Sweden was also searched on the Fass website (2016) and inserted in this

work as a search engine, as they showed the results of drugs and medicines ecotoxicity tests conducted by drug registration holders.

The ecotoxicity results were discussed from a comparative perspective and analysis of the information obtained. One of the parameters used was the classification of acute ecotoxicity shown in Table 1, proposed by ZUCKER (1985) (Zucker, 1985). Furthermore, chronic toxicity data were also evaluated.

| Parameter | Concentration mg/L |
|--------------------------------------|--|
| CL ₅₀ or CE ₅₀ | <0.1 |
| CL ₅₀ or CE ₅₀ | 0.1 - 1 |
| CL ₅₀ or CE ₅₀ | 1 - 10 |
| CL ₅₀ or CE ₅₀ | 10 - 100 |
| CL ₅₀ or CE ₅₀ | >100 |
| | CL ₅₀ or CE ₅₀ CL ₅₀ or CE ₅₀ CL ₅₀ or CE ₅₀ CL ₅₀ or CE ₅₀ |

Table 1. Acute ecotoxicity parameters.

Source: Zucker (1985).

3. Results and discussion

Understanding drug elimination aspects is crucial to estimating the percentage not metabolized that is eliminated and knowing the most common metabolites. The physicochemical properties are important parameters to predict some behavior of substances in the environment. Table 2 shows the estimates of drug elimination by the human body in unaltered form and its primary metabolites.

| Drug | Recommended daily dose (mg)* | Elimination in unchanged form of drug (%) | | Metabolites | | |
|---------------|---------------------------------|---|-----------|--|--|--|
| | | Urine | Faeces | | | |
| Abacavir | 600 | 1.2 | 16 | 5'-carboxylic (30%); 5'-glucuronide (36%); other metabolites (15%) | | |
| Atazanavir | 300 | 7 | 20 | - | | |
| Darunavir | 1200 | 7.7 | 41.2 | - | | |
| Didanosine** | - | - | - | - | | |
| Dolutegravir | 50 | <1 | 53 | glucuronide ether (18.9%); N-dealkylation metabolite (3.6%); metabolite formed by the oxidation of benzyl carbon (3.0%) | | |
| Efavirenz | 600 | <1 | 16-61ª | 7-hydroxy-efavirenz; 8-hydroxy-efavirenz; 8,14- dihydroxy-efavirenz | | |
| Enfuvirtide | 180 | - | - | amino acids | | |
| Emtricitabine | 200 | 73 | 14 | 3'-sulfoxide daystereoisomers; 2'-O-glucuronide | | |
| Etravirine | 400 | - | 81.2-86.4 | - | | |
| Fosamprenavir | 1400 | - | 1% | - | | |
| Lamivudine | 300 | ~70% | - | Lamivudine Sulfoxide, Lamivudine 5' triphosphate | | |
| Lopinavir | 800 | 2.2 | 19.8 | 12 different metabolites; oxidation metabolites | | |
| Maraviroc | 600 | 8 | 25 | Various metabolites | | |
| Nevirapine | 400 | <3 | - | 2-hydroxynevirapine glucuronide 3-hydroxynevirapine glucuronide 8-hydroxynevirapine glucuronide 12-hydroxynevirapine glucuronide 4-carboxynevirapine | | |
| Raltegravir | 400 | 9 | - | raltegravir-glucuronide | | |
| Ritonavir | 400 | 3.5 | 33.8 | isopropylthiazolyl oxidation metabolite | | |
| Saquinavir** | - | - | - | | | |
| Tenofovir | 300 | 70-80 | - | tenofovir alafenamide | | |
| Tipranavir | 1000 | - | 52 | hydroxylated metabolite and glucuronide | | |
| Zidovudine | 600 | 29 | - | 3'-azido-3'-deoxy-5'-O-beta- Dglucopyranuronosylthymidine, isomeric addition cycle products | | |

Table 2. Data on the elimination of antiretrovirals found in the 2020 List dispensed in Brazil.

* Recommended doses for adults. In cases where doses are variable, the highest recommended doses were used. **Drugs excluded from RENAME 2020. Source: Authors (2022).

According to data from one of the ARV dispensing units in Belo Horizonte (MG), Table 3, we observed an increase of around 20% in the total amount of ARV dispensed from 2018 to 2020, representing approximately 52 kg of ARVs disposed of into the environment. In 2020, more than 2,400,000 ARV pharmacotechnical units were dispensed in this dispensing unit alone to approximately 3,479 people. The highest percentages in the last year were of dolutegravir, lamivudine, and tenofovir, emphasizing the growing number of units of these drugs over the observed triennium, resulting from the guideline that established in 2017 this combination as first-line therapy in the treatment of HIV infection in Brazil. According to data from the Brazilian Ministry of Health, 12,833 PLHIV were on ART (Brazil 665,799) in Belo Horizonte in 2020 (BRASIL, 2022). Thus, based on the proportion of PLHIV using the first-line therapeutic regimen achieved for the Belo Horizonte ARV unit evaluated, at the recommended dosage of one tablet of dolutegravir 50 mg + a tablet of tenofovir 300 mg associated with

Lamivudine 300 mg administered daily, the estimated amount of ARV dispensed to individuals and eliminated unchanged into the environment in Belo Horizonte and Brazil was approximately 559 kg and 28,902 kg, respectively, as shown in Table 4.

| Drug | Drug Pharmaceutical Concentration form | | Drug elimination rate in unchanged | Number | annua | Annual estimate of annual elimination (Kg) in the environment | | | |
|------------------------|---|---------------|---|---------------------|-----------------|---|------|------|------|
| | | | form (%) | 2018 | 2019 | 2020 | 2018 | 2019 | 2020 |
| Abacavir | 300mg | Tablet | 17.2 | 59,100 (2.9 %) | 45,360 (2.1%) | 41,880 (1.7%) | 3.0 | 2.3 | 2.2 |
| Abacavir | 20mg/ml | Oral solution | 17.2 | 4 (0%) | 0 (0%) | 8 (0%) | 0.0 | 0.0 | 0.0 |
| Atazanavir | 300mg | Capsule | 27 | 207,300 (10.2 %) | 178,230 (8.2%) | 168,210 (6.9%) | 16.8 | 14.4 | 13.6 |
| Darunavir | 600mg | Tablet | 48.9 | 140,160 (6.9%) | 143,400 (6.6%) | 155,880 (6.4%) | 41.1 | 42.1 | 45.7 |
| Dolutegravir | 50mg | Tablet | 53 | 194,310 (9.6%) | 373,140 (17.2%) | 532,380 (21.7%) | 5.1 | 9.9 | 14.1 |
| Efavirenz | 600mg | Tablet | 39 | 37,650 (1.9%) | 29,850 (1.4%) | 26,610 (1.1%) | 8.8 | 7.0 | 6.2 |
| Efavirenz | 30mg/ml | Oral solution | 39 | 7 (0%) | 0 (0%) | 8 (0%) | 0.0 | 0.0 | 0.0 |
| Etravirina | 200mg | Tablet | 83.8 | 4,620 (0.2%) | 5,100 (0.2%) | 4,500 (0.2%) | 0.8 | 0.9 | 0.8 |
| Lamivudine | 150mg | Tablet | 70 | 79,440 (3.9%) | 103,080 (4.7%) | 134,940 (5.5%) | 8.3 | 10.8 | 14.2 |
| Lamivudine* | 10mg/ml | Oral solution | 70 | 19,920 (1.0%) | 8,880 (0.4%) | 20,640 (0.8%) | 0.4 | 0.2 | 0.4 |
| Lopinavir + Ritonavir* | 80+20mg/ml | Oral solution | 15 | 4,320 (0.2%) | 320 (0%) | 0 (0%) | 0.1 | 0.0 | 0.0 |
| Maraviroc | 150mg | Tablet | 25 | 1,320 (0.1%) | 1,380 (0.1%) | 1,380 (0.1%) | 0.0 | 0.1 | 0.1 |
| Nevirapine | 200mg | Tablet | 1 | 26,760 (1.3%) | 18,060 (0.8%) | 16,320 (0.7%) | 0.1 | 0.0 | 0.0 |
| Raltegravir | 400mg | Tablet | 42 | 3,960 (0.2%) | 3,240 (0.1%) | 3,420 (0.1%) | 0.7 | 0.5 | 0.6 |
| Ritonavir | 100mg | Tablet | 18.7 | 328,320 (16.1%) | 291,300 (13.4%) | 283,650 (11.6%) | 6.1 | 5.4 | 5.3 |

Table 3. Data on dispensing and disposal of antiretrovirals from a drug dispensing unit in Belo Horizonte (MG), Brazil.

| Drug | Drug Pharmaceuti Concentration form | | Drug elimination rate in unchanged | Number of | f pharmaceutical u | Annual estimate of annual elimination (Kg) in the environment | | | |
|--------------------------------|--|---------|---|--------------------|--------------------|---|-------|-------|-------|
| | | | form (%) | 2018 | 2019 | 2020 | 2018 | 2019 | 2020 |
| Tenofovir | 300mg | Tablet | 75 | 5,280 (0.3%) | 3,150 (0.1%) | 3,180 (0.1%) | 1.2 | 0.7 | 0.7 |
| Tenofovir+Lamivudine | 300mg+300mg | Tablet | 75 | 378,600 (18.6%) | 508,530 (23.4%) | 637,680 (26.0%) | 170.4 | 228.8 | 287.0 |
| Tenofovir+Lamivudine+Efavirenz | 300mg+300mg+ 600mg | Tablet | 61 | 418,710 (20.6%) | 343,170 (15.8%) | 322,200 (13.1%) | 306.5 | 251.2 | 235.9 |
| Zidovudine | 100mg | Capsule | 29 | 3,400 (0.2%) | 1,900 (0.1%) | 400 (0%) | 0.1 | 0.1 | 0.0 |
| Zidovudine + Lamivudine | 300mg+150mg | Tablet | 49.5 | 144,840 (7.1%) | 125,520 (5.8%) | 121,500 (5.0%) | 32.3 | 28.0 | 27.1 |
| | | | Total | 2,033,891 | 2,174,449 | 2,454,232 | 601.8 | 602.4 | 653.8 |

Table 3. Data on dispensing and disposal of antiretrovirals from a drug dispensing unit in Belo Horizonte (MG), Brazil (Cont.)

Source: Authors (2022).

| | | | Belo Horizonte annual estimate Brazil annual esti | | | estimate |
|--------------|--------------------|-------------------------------------|---|---|----------------------------|---|
| Drug | Daily dose (mg) | Elimination in unchanged form | Pharmacotechnical units | Disposal in (Kg) in the environment | Pharmacotechnical units | Disposal in (Kg) in the environment |
| Dolutegravir | 50 | 54% | 4,684,045 | 126.5 | 243,016,635 | 6,561.4 |
| Tenofovir | 300 | 75% | 4,684,045 | 1053.9 | 243,016,635 | 54,678.7 |
| Lamivudina | 300 | 70% | 4,684,045 | 983,6 | 243,016,635 | 51,033.5 |
| | | | Total | 2,163,4 | Total | 112,276.6 |

| Table 4. Estimated annual elimination of ARVs in unchanged form in Belo Horizonte and Brazil in 2020. |
|--|
|--|

Source: Authors (2022).

These estimates corroborate those described for South Africa, the African country with the most extensive program to combat and prevent HIV infection, which serves more than 5.25 million PLHIV with ART, where it is estimated that 4.32 tons of ARVs are consumed daily, equivalent to approximately 1,576 tons per year (Ncube et al., 2018). We emphasize that these drugs, although released in significant amounts into the environment, are successively diluted in effluents and water bodies and found in ng/mL and pg/mL (Nannou et al., 2020).. Considering also that many of the effluent, sewage, and water treatment systems are not designed to eliminate this type of contaminant, besides the recalcitrant characteristics of some ARVs, there are imminent risks for developing resistant viral strains and possible ecosystem changes in contact with these pollutants (Muriuki et al., 2020; Nannou et al., 2020; Ncube et al., 2018).

Regarding the existing ecotoxicological studies on ARVs dispensed by the Brazilian Unified Health System (SUS) and included in RENAME (2020), after researching databases, we selected four articles with results of acute or chronic toxicity in ecotoxicological models involving ARVs, Figure 2. We did not identify any mention of ecotoxicology involving the ARVs atazanavir, daclatasavir, didanosine, enfurvitide, emtricitrabine, lopinavir, saquinavir and sofosvubir.




Figure 2. Flow of selection of ecotoxicity articles for selected ARVs.

Source: Authors (2022).

| Table 5. Complete data on th | e ecotoxicity of ARV | s dispensed by the Brazil | ian Unified Health System (SUS). |
|------------------------------|----------------------|---------------------------|----------------------------------|
| | | | |

| Antiretroviral | Species | Aquatic organism | Kind of study | Period | Parameter | Result (mg/L) | Methodology | Reference |
|----------------|-------------------------------------|---------------------|------------------|--------|------------------|------------------|-------------|------------------------|
| Abacavir | Daphnia magna | Crustacea | Acute | 48h | EC ₅₀ | >100 | | (Minguez et al., 2016) |
| | Pseudokirchneriell a subcapitata | Alga | Acute | 72h | EC_{50} | 57.32 | | |
| | Artemia salina | Crustacea | Acute | 48h | EC ₅₀ | >100 | | |
| | Skeletonema marinoi | Bacteria | Acute | 72h | CE ₅₀ | NA | | |
| Atazanavir | NR | | | | | | | |
| Daclatasvir | NR | | | | | | | |

| Antiretroviral | Species | Aquatic organism | Kind of study | Period | Parameter | Result (mg/L) | Methodology | Reference |
|------------------------------|------------------------------------|---------------------|---------------|--------------|------------------|------------------|-------------|--|
| Darunavir | Pseudokirchneriella | Algo | Acute | 72h | CE50 | >43 | OECD 201 | (FASS, 2016) |
| | subcapitata | Alga | Acute | /211 | NOEC | 43 | OECD 202 | |
| | Daphnia | Crustacea | Acute | 48h | EC50 | >44 | OECD 202 | |
| | magna | Crustacea | Acute | 4011 | NOEC | 2.6 | | |
| | Oncorhynchuss | Fish | Acute | 0.11 | CL50 | >38 | OECD 203 | |
| | mykiss | | | 96h | NOEC | 38 | OECD 203 | |
| | Daphnia magna | Crustacea | Chronic | 21 days | NOEC | 19 | OECD 211 | |
| | Pimephales promelas | Fish | Chronic | 28 days | NOEC | 9.4 | OECD 210 | |
| Didanosine | NR | | | | | | | (FASS, 2016) |
| Dolutegravir | Pseudokirchneriella subcapitata | Alga | Acute | 96h | CI50 | 0.233 | OECD 201 | (FASS, 2016) |
| | subcapitata | | | <i>y</i> 011 | NOEC | 0.095 | OECD 201 | |
| | Daphnia magna | Crustacea | Acute | 48h | CE50 | >6.430 | OECD 202 | |
| | Daphnia magna | Crustacea | Chronic | 21 days | NOEC | 0.834 | OECD 211 | |
| | Juvenile Pimephales promelas | Fish | Chronic | 28 days | NOEC | 0.22 | OECD 210 | |
| Efavirenz | Selenastrum capricornutum | Alga | Chronic | 10.1 | CE50 | >0.026 | FDA 4.01 | (FASS, 2016) |
| | | | | 12 days | NOEC | 0.026 | FDA 4.01 | |
| | Daphnia magna | Crustacea | Acute | 48h | EC ₅₀ | 1.1 | FDA 4.08 | |
| | Lepomis macrochirus | Fish | Acute | 96h | CL_{50} | 0.85 | FDA 4.11 | |
| | Daphnia magna | Crustacea | Chronic | 21 days | NOEC | 0.16 | OECD 211 | |
| | Pimephales promelas | Fish | Chronic | 33 days | NOEC | 0.07 | OCDE 210 | |
| | Oreochromis mossambicus | Fish | Chronic | 7 days | LOEC | 0.0000103 | | (Robson, Barnhoorn, & Wagenaar, 2017) |
| Emtricitabine Enfuvirtide | NR NR | | | | | | | |
| Etravirine | Scenedesmus subspicatus | Alga | Acute | 72h | CE ₅₀ | >0.0049 | OECD 201 | (FASS, 2016) |
| | | | | | NOEC | 0.0049 | OECD 202 | |
| | Daphnia magna | Crustacea | Chronic | 21 days | NOEC | 0.0091 | OECD 211 | |
| | Brachydanio rerio | Fish | Chronic | 35 days | NOEC | 0.01 | OECD 210 | |

Table 5. Complete data on the ecotoxicity of ARVs dispensed by the Brazilian Unified Health System (SUS) (Cont.)

| Antiretroviral | Species | Aquatic organism | Kind of study | Period | Parameter | Result (mg/L) | Methodology | Reference |
|----------------|------------------------------------|---------------------|------------------|---------|------------------|-----------------------|-------------|---|
| Fosamprenavir | Selenastrum caprocornutum | Alga | Acute | 72h | Cl ₅₀ | >100 | OECD 201 | (FASS, 2016) |
| | • | | | | NOEC | 100 | OECD 201 | |
| | Daphnia magna | Crustacea | Acute | 48h | CE50 | >109 | OECD 202 | |
| | | | | | NOEC | 109 | OECD 202 | |
| | Juvenilee Ocorhynchus mykiss | Fish | Acute | 96h | CL50 | >100 | OECD 203 | |
| | | Crasta ana | Chaomio | 7 dava | NOEC | 100 | OECD 203 | |
| Lamivudine | Ceriodaphnia dubia Selenastrum | Crustacea | Chronic | / days | NOEC | 100 | EPA 1002 | (FASS, 2016) |
| Lainivuunie | caprocornutum | Alga | Acute | 72h | CI50 | >96.9 | OECD 201 | (FASS, 2010) |
| | | | | | NOEC | >96.9 | OECD 201 | |
| | Daphnia magna | Crustacea | Acute | 48h | CE50 | >1000 | OECD 202 | |
| | Daphnia magna | | | | NOEC | >1000 | OECD202 | |
| | Juvenilee | C · | A . | 0.01 | CL ₅₀ | >97.7 | OECD 203 | |
| | Oncorhyncus mykiss | Crustacea | Acute 9 | 96h | NOEC | 97.7 | OECD 203 | |
| | | | | | CE50 | >100 | EPA 1002 | |
| | Ceriodaphnia dubia | Crustacea | a Chronic | 7 days | NOEC | 100 | EPA 1002 | |
| | | | | | CE50 | >100 | OECD 211 | |
| | Daphnia magna | Crustacea | Chronic | 21 days | NOEC | 100 | OECD 211 | |
| | Pimephales | Eich Chaoni | ~ . | . 0.1 | CL_{50} | >10 | OECD 210 | |
| | promelas | Fish | Chronic | 96h | NOEC | 10 | OECD 210 | |
| Lopinavir | NR | | | | | | | |
| Maraviroc | Pseudokirchneriella subcapitata | Alga | Acute | 72h | CI ₅₀ | >115 | OECD 201 | (FASS, 2016) |
| | Daphnia magna | Crustacea | Acute | 48h | CE50 | >69 | OECD 202 | |
| | Juvenile Ocorhynchus mykiss | Fish | Acute | 96h | CL ₅₀ | >73 | OECD 203 | |
| | Ceriodaphnia dubia | Crustacea | Chronic | 7 days | NOEC | 92 | EPA 1002 | |
| Nevirapine | Selenastrum capricornutum | Alga | Chronic | 10 days | CE50 | >43 | FDA 4.01 | (FASS, 2016) |
| | I | | | | NOEC | 43 | FDA 4.01 | |
| | Daphnia magna | Crustacea | Acute | 48h | CE50 | 76.9 | 92/69/EEC | |
| | | Crustacea | Acuit | -1011 | NOEC | 76.9 | 92/69/EEC | |
| | Oncorhynchus mykiss | Fish | Acute | 96h | CL50 | >65 | 92/69/EEC | |
| | Pimephales promelas | Fish | Acute | 96h | CL50 | >99 | FDA 4.11 | |
| Nevirapine | Oreochromis mossambicus | Fish | Chronic | 30 days | NOEC | 1,48x10 ⁻⁶ | | (NIBAMUREK; BARNHOORN; WAGENAAR, 2019) |

Table 5. Complete data on the ecotoxicity of ARVs dispensed by the Brazilian Unified Health System (SUS) (Cont.)

| Antiretroviral | Species | Aquatic organism | Kind of study | Period | Parameter | Result (mg/L) | Methodology | Reference |
|----------------|-----------------------------------|---------------------|------------------|------------------|--------------------------|------------------|----------------------|-------------------------|
| Raltegravir | Selenastrum capricornutum | Alga | Acute | 96h | CE ₅₀ | 66 | OECD 201 | (FASS, 2016) |
| | | | | | NOEC | 3.8 | OECD 201 | |
| | Daphnia magna | Crustacea | Acute | 48h | CL50 | >100 | OECD 202 | |
| | Pimephales promelas | Fish | Acute | 96h | CL50 | >100 | OECD 203 | |
| | Cyprinodon variegatus | Fish | Acute | 96h | CL ₅₀ | >100 | OECD 203 | |
| | Daphnia magna | Crustacea | Chronic | 21 days | NOEC | 9.5 | OECD 211 | |
| | Pimephales promelas | Fish | Chronic | 33 days | NOEC | 9.3 | OECD 210 | |
| Ritonavir | Daphnia magna | Crustacea | Acute | 48h | CE50 | >1.5 | FDA 4.08 | (FASS, 2016) |
| | Hyalella azteca | Crustacea | Acute | 96h | NOEC | 1.59 | FDA 4.10 | |
| | Lepomis macrochirus | Fish | Acute | 24,48,7 2,96h | CL ₅₀ | >1.63 | FDA 4.11 | |
| Saquinavir | NR | | | | | | | |
| Sofosbuvir | NR | | | | | | | (EASS 2016) |
| Tenofovir | seudokirchneriella subcapitata | Alga | Acute | 72h | CE ₅₀ | 69 | OECD 201 | (FASS, 2016) |
| | | | | | NOEC | 18 | OECD 201 | |
| | Daphnia magna | Crustacea | Chronic | 21days | NOEC | 12 | OECD 211 | |
| | Pimephales promelas | Fish | Chronic | - | NOEC | 9 | OECD 210 | |
| | Aliivibrio fischeri | Bacteria | Acute | 15 min | EC ₅₀ | 14.83 | | (Silva et al., 2019) |
| | Artemia salina | Crustacea | Acute | 36h | EC ₅₀ | 111.82 | | 2019) |
| | Microcystis novacekii | Bacteria | Chronic | 12 days | LOEC | 161.01 | | |
| Tipranavir | Desmodesmus subspicatus | Alga | Acute | 96h | EC ₅₀ | >40.4 | OECD 201 | (FASS, 2016) |
| | Daphnia magna | Crustacea | Acute | 48h | EC ₅₀ NOEC | 5 3.96 | OECD 202 OECD 202 | |
| | Oncorhynchus | Fish | Acute | 96h | EC ₅₀ | 15.4 | OECD 203 | |
| | mykiss | | | | NOEC | 1 | OECD 203 | |
| Zidovudin3 | Daphnia magna | Crustacea | Acute | 48h | EC ₅₀ | >1.000 | OECD 202 | (FASS, 2016) |
| | | | | | NOEC | 16 | OECD 202 | |
| | | | Chronic | 21 days | EC ₅₀ | >100 | OECD 209 | |
| | | | Chronic | 21 auys | NOEC | >16 | OECD 209 | |

Table 5. Complete data on the ecotoxicity of ARVs dispensed by the Brazilian Unified Health System (SUS) (Cont.)

NR - No results

Source: Authors (2022).

Considering the parameters presented by Zucker (1985) (Table 1) regarding environmental toxicity, we could say that dolutegravir and efavirenz are highly toxic. Etravirine can be classified as very highly toxic. Tipranavir and ritonavir can be classified as moderately toxic. Abacavir, darunavir, lamivudine, maraviroc, and tenofovir can be classified as mildly toxic. Darunavir, lamivudine, and maraviroc have toxicity values above 38 mg/L, 96.9 mg/L, and 73 mg/L, respectively. Fosamprenavir and zidovudine are practically nontoxic.

We should note that most ARVs do not reach a concentration of 0.1 mg/L in domestic effluent treatment plants or the environment (Nannou et al., 2020). Muriuki et al. (2020) detected a concentration of 1.4635 mg/L for lamivudine in an effluent treatment plant in Kenya. High concentrations are expected in industrial effluent treatment plants. A study with real effluents from a zidovudine and lamivudine production plant found drug concentrations of 6.29 mg/L and 3.22 mg/L, respectively (Souza, et al., 2010). Therefore, even if a drug is classified as highly toxic and by the studies currently published, there is an indication that the values of environmental concentrations are low. However, higher concentrations can be achieved in industrial effluents.

According to the information shown in Table 5, we can observe that drugs darunavir, fosamprenavir, lamivudine, maraviroc, raltegravir, tenofovir, and zidovudine have high values for NOEC, which in practice are not observed in the environment or a domestic effluent treatment plant (Nannou et al., 2020). Darunavir, lamivudine, and tenofovir have NOEC values below 10 mg/L, which are possible concentrations in a pharmaceutical effluent. Regarding concentration in industrial effluents, the work by Souza et al. (2010) shows that the maximum concentrations of zidovudine and lamivudine, which are 6.29 mg/L and 3.22 mg/L respectively, do not come close to the NOECs for these substances.

Dolutegravir presented a NOEC value of 0.22 mg/L for the fish species *Juvenile Pimephales promelas*. It is challenging to consider the result as data indicating its concentration in the environment or effluent treatment plants were not found in the literature. Etravirine had a NOEC value of 0.0091 mg/L for the crustacean *Daphnia magna*. Although the concentration of NOEC is low, no data on the concentration in the environment and effluent treatment plants is available. We should emphasize that etravirine is not a first-choice drug in Brazil; therefore, its use is reduced.

The chronic toxicity test performed for nevirapine was presented in a paper by Nibamureke et al. (2019). The maximum concentration of the drug found in raw water in South Africa was used in the study, which was 1.48x10⁻⁶ mg/L, determined as NOEC. The study followed OECD guidelines for toxicity testing. It is worth noting that this was the only concentration evaluated (Nibamureke et al., 2019). There are no acute toxicity studies for the species of fish used in the study cited. However, we found some acute toxicity studies with other fish for nevirapine, which promotes toxic effects at concentrations above 65 mg/L. Thus, the NOEC value presented by the paper may be below the actual value. There is no other work or information regarding the chronic toxicity of nevirapine.

Only efavirenz has the result presented as LOEC. The study by Robson et al. (2017) aimed to assess the influence of the maximum concentration of efavirenz in water bodies in the Limpopo province, South Africa (Robson et al., 2017). The maximum concentration was 10.3 ng/l ($1.03x10^{-5}$ mg/L). Tests conducted with *Oreochromis mossambicus* (Tilapia from Mozambique) and histological analysis showed that the concentration induced deleterious effects on the animal's liver. Moreover, a concentration of 20.6 ng/l ($2.06x10^{-5}$ mg/L) was found and induced effects in the liver and other organs. We should emphasize that this study did not follow any international standards for the development of the tests, and only two concentrations were used, the one that appears in the environment and its double. Thus, it is impossible to affirm whether concentrations lower than $1.03x10^{-5}$ mg/L can harm the species. Despite the details, the study obtained important information about the drug.

Although efavirenz was analyzed based on the results of Robson et al. (2017), as the tests did not follow registered protocols, it is interesting to assess chronic toxicity from a second test performed following recognized protocols. As a result, the data obtained through the fass.se website show that the FDA protocols were used. The test was performed with algae for 12 days, and the EC_{50} was determined to be greater than 0.026 mg/L and the NOEC equal to 0.026 mg/L for the species *Selenastrum capricornutum*. Based on other research, we can affirm that the concentrations found in the environment and in domestic effluent treatment plants for this drug do not exceed the NOEC value et al., 2017).

4. Conclusion

Ecotoxicological studies involving antiretrovirals are scarce, and further research with as many of these drugs as possible is required. With significant numbers of medicines used by people living with HIV, it is urgent to quantify the main ARVs in water bodies. With this information and ecotoxicological data, we can establish risk criteria for eventual control or mitigation measures of these contaminants in the environment, mainly to improve the effluent and water treatment of large urban centers. We should also point out that the chronic toxicity of ARVs must be prioritized, especially those with greater consumption and elimination in the unchanged form and considered low-risk in acute toxicity studies or environmental risk assessment. As noted for efavirenz, the concentration at which a chronic effect is observed may be well below the concentration of the not observed effect. The toxicity studies presented were conducted with the drugs in isolation, so further research should be performed to understand the toxic capacity of these substances in complex systems, such as tablets or industrial or domestic effluent.

We strongly encourage the development of new models and ecotoxicological research involving organisms native to the countries, in order to expand the monitoring and knowledge of the environmental impacts caused by organic pollutants, especially drugs.

Funding

This work was supported by FAPEMIG, File N° APQ-02426-21, for the support for developing the research.

Conflict of interest

The authors declare no conflict of interest.

References

ABNT. (2022). Entidade responsável pela elaboração das Normas Brasileiras (ABNT NBR), elaboradas por seus Comitês Brasileiros (ABNT/CB), Organismos de Normalização Setorial (ABNT/ONS) e Comissões de Estudo Especiais (ABNT/CEE). Associação Brasileira de Normas técnicas website: https://www.abnt.org.br/

Akkari, A. C. S., Munhoz, I. P., Tomioka, J., Dos Santos, N. M. B. F., & Dos Santos, R. F. (2016). Inovação tecnológica na indústria farmacêutica: Diferenças entre a Europa, os EUA e os países farmaemergentes. *Gestao e Producao*, 23(2), 365–380. https://doi.org/10.1590/0104-530X2150-15

Aquino, S. F., Brandt, E. M. F., & Chernicharo, C. A. de L. (2013). Remoção de fármacos e desreguladores endócrinos em estações de tratamento de esgoto: Revisão da literatura. *Engenharia Sanitaria e Ambiental*, *18*(3), 187–204. https://doi.org/10.1590/S1413-41522013000300002

BRASIL. (2019). Relação Nacional de Medicamentos Essenciais 2020 (M. da Saúde, Ed.). Brasília-DF: Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde. Departamento de Assistência Estratégicos, Farmacêutica e Insumos.

BRASIL. (2020). Boletim Epidemiológico HIV / Aids | 2020. Secretaria de Vigilância Em Saúde / Ministério Da Saúde, 1, 68. http://www.aids.gov.br/pt-br/pub/2020/boletim-epidemiologico-hivaids-2020

BRASIL. (2022). Vigilância Epidemiológica - Indicadores clínicos do HIV. Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Miistério da Saúde website: http://www.aids.gov.br/pt-br/publico-geral/hiv/vigilancia-epidemiologica

Brito, N. N., & Marinho Silva, V. B. (2012). Processo Oxidativo Avançado E Sua Aplicação Ambiental. *REEC - Revista Eletrônica de Engenharia Civil*, 3(1), 36–47. https://doi.org/10.5216/reec.v3i1.17000

CONAMA. (2005). Resolução 357/2005. Dispõe Sobre a Classificação Dos Corpos de Água e Diretrizes Ambientais Para o Seu Enquadramento, Bem Como Estabelece as Condições e Padrões de Lançamento de Efluentes, e Dá Outras Providências., (53), 58–63.

CONAMA. (2011a). Resolução 430/2011. Dispõe Sobre Condições e Padrões de Lançamento de Efluentes, Complementa e Altera a Resolução No 357, de 17 de Março de 2005, Do Conselho Nacional Do Meio Ambiente - CONAMA., (92), 89.

CONAMA. Resolução CONAMA nº 430, de 13 de Maio de 2011., Diário Oficial da União § (2011).

Costa, C. R., Olivi, P., Botta, C. M. R., & Espindola, E. L. G. (2008). A toxicidade em ambientes aquáticos: Discussão e métodos de avaliação. *Química Nova*, 31(7), 1820–1830. http://static.sites.sbq.org.br/quimicanova.sbq.org.br/pdf/Vol31No7_1820_37-RV07485.pdf

Cronin, M. A., & George, E. (2020). The Why and How of the Integrative Review. Organizational Research Methods, 1–25. https://doi.org/10.1177/1094428120935507

FASS. (2016). FASS.SE. In Collaborative Website of Swedish Pharmaceutical Companies That Provides Information about Medicines Marketed in Sweden. Retrieved from https://www.fass.se/LIF/startpage

Fioreze, M., Santos, E. P. dos, & Schmachtenberg, N. (2014). Processos oxidativos avançados: Fundamentos e aplicação ambiental. *Revista Eletrônica Em Gestão, Educação e Tecnologia Ambiental, 18*(1), 79–91. https://doi.org/10.5902/2236117010662

Gazola, L. (2020). Análise das legislações estaduais brasileiras sob ensaios ecotoxicológicos como ferramenta no controle de lançamento de efluentes industriais (Dissertação de mestrado - Universidade Federal de Santa Catarina). https://repositorio.ufsc.br/bitstream/handle/123456789/216418/PPCA0047-D.pdf?sequence=-1&isAllowed=y

Trata Brasil. (2021). Ranking Instituto Trata Brasil 2021 2019) (Vol. 2021). Instituto DoSaneamento (Snis https://tratabrasil.org.br/images/estudos/Ranking_saneamento_2021/Relatório_-_Ranking_Trata_Brasil_2021_v2.pdf

Jain, S., Kumar, P., Vyas, R. K., Pandit, P., & Dalai, A. K. (2013). Occurrence and removal of antiviral drugs in environment: A review. *Water, Air, and Soil Pollution*, 224(2). https://doi.org/10.1007/s11270-012-1410-3

Kornis, G. E. M., Braga, M. H., & de Paula, P. A. B. (2014). Transformações recentes da indústria farmacêutica: Um exame da experiência mundial e Brasileira no século XXI. *Physis*, 24(3), 885–908. https://doi.org/10.1590/S0103-73312014000300012

Kumar, M., Mazumder, P., Mohapatra, S., Kumar Thakur, A., Dhangar, K., Taki, K., & Kuroda, K. (2021). A chronicle of SARS-CoV-2: Seasonality, environmental fate, transport, inactivation, and antiviral drug resistance. *Journal of Hazardous Materials*, 405(336). https://doi.org/10.1016/j.jhazmat.2020.124043

Magalhães, D. de P., & Ferrão-Filho, A. da S. (2008). A Ecotoxicologia como ferramenta no Biomonitoramento de Ecossistemas Aquáticos. *Oecologia* Australis, 12(03), 355–381. https://doi.org/10.4257/oeco.2008.1203.02

Minguez, L., Pedelucq, J., Farcy, E., Ballandonne, C., Budzinski, H., & Halm-Lemeille, M. P. (2016). Toxicities of 48 pharmaceuticals and their freshwater and marine environmental assessment in northwestern France. *Environmental Science and Pollution Research*, 23(6), 4992–5001. https://doi.org/10.1007/s11356-014-3662-5

Muriuki, C., Kairigo, P., Home, P., Ngumba, E., Raude, J., Gachanja, A., & Tuhkanen, T. (2020). Mass loading, distribution, and removal of antibiotics and antiretroviral drugs in selected wastewater treatment plants in Kenya. *Science of the Total Environment*, 743, 140655. https://doi.org/10.1016/j.scitotenv.2020.140655

Nannou, C., Ofrydopoulou, A., Evgenidou, E., Heath, D., Heath, E., & Lambropoulou, D. (2020). Antiviral drugs in aquatic environment and wastewater treatment plants: A review on occurrence, fate, removal and ecotoxicity. *Science of the Total Environment*, 699, 134322. https://doi.org/10.1016/j.scitotenv.2019.134322

Ncube, S., Madikizela, L. M., Chimuka, L., & Nindi, M. M. (2018). Environmental fate and ecotoxicological effects of antiretrovirals: A current global status and future perspectives. *Water Research*, Vol. 145, pp. 231–247. https://doi.org/10.1016/j.watres.2018.08.017

Nibamureke, U. M. C., Barnhoorn, I. E. J., & Wagenaar, G. M. (2019). Hatching success and survival of fish early life stages in a chronic exposure to nevirapine: a case study of the Mozambique tilapia. *International Journal of Environmental Health Research*, 29(4), 441–456. https://doi.org/10.1080/09603123.2018.1548697

Prasse, C., Schlüsener, M. P., Schulz, R., & Ternes, T. A. (2010). Antiviral drugs in wastewater and surface waters: A new pharmaceutical class of environmental relevance? *Environmental Science and Technology*, 44(5), 1728–1735. https://doi.org/10.1021/es903216p

Rashed, M. N. et al. (2022). Persistent Organic Pollutants (POPs). https://doi.org/10.5772/intechopen.95151

Robson, L., Barnhoorn, I. E. J., & Wagenaar, G. M. (2017). The potential effects of efavirenz on Oreochromis mossambicus after acute exposure. Environmental Toxicology and Pharmacology, 56(September), 225–232. https://doi.org/10.1016/j.etap.2017.09.017

Schoeman, C., Dlamini, M., & Okonkwo, O. J. (2017). The impact of a Wastewater Treatment Works in Southern Gauteng, South Africa on efavirenz and nevirapine discharges into the aquatic environment. *Emerging Contaminants*, 3(2), 95–106. https://doi.org/10.1016/j.emcon.2017.09.001

SILVA, S. R. et al. Toxicity for Aquatic Organisms of Antiretroviral Tenofovir Disoproxil. Journal of Environmental Protection, v. 10, n. 12, p. 1565–1577, 2019. https://doi.org/10.4236/jep.2019.1012093

Souza, S. J. O., Lobo, T. M., Sabino, A. L. O., Oliveira, S. B., & Costa, O. S. (2010). Decomposição dos Antirretrovirais Lamivudina e Zidovudina pelo Processo Fotofenton Assistido no Efluente de Indústria Farmoquímica. *Revista Processos Químicos*, 4(7), 59–67. https://doi.org/10.19142/rpq.v4i7.108

UNAIDS. (2021). Global Hiv Statistics. https://www.unaids.org/en/resources/fact-sheet

Tang, Y., Yin, M., Yang, W., Li, H., Zhong, Y., Mo, L., & Sun, X. (2019). Emerging pollutants in water environment: Occurrence, monitoring, fate, and risk assessment. *Water Environment Research*, *91*(10), 984–991. https://doi.org/10.1002/wer.1163

Von Sperling, M. (1996). Princípio do tratamento biológico de águas residuárias (2nd ed.). Belo Horizonte.

Whittemore, R., & Knafl, K. (2005). The integrative review: Updated methodology. *Journal of Advanced Nursing*, 52(5), 546–553. https://doi.org/10.1111/j.1365-2648.2005.03621.x

Zagatto, P. A., & Bertoletti, E. (2006). Ecotoxicologia aquática: princípios e aplicações (Primeira; E. Rima, Ed.). São Carlos.

Zenker, A., Cicero, M. R., Prestinaci, F., Bottoni, P., & Carere, M. (2014). Bioaccumulation and biomagnification potential of pharmaceuticals with a focus to the aquatic environment. *Journal of Environmental Management*, *133*, 378–387. https://doi.org/10.1016/j.jenvman.2013.12.017

Zucker, E. (1985). Acute toxicity test for freshwater invertebrates. Hazard Evaluation Division, Standard Evaluation Procedure, (June), 1–12.